Journal: Experimental & Molecular Medicine

Article Title: RETRACTED ARTICLE: Downregulation of the long noncoding RNA MBNL1-AS1 protects sevoflurane-pretreated mice against ischemia-reperfusion injury by targeting KCNMA1

doi: 10.1038/s12276-018-0133-y

Figure Lengend Snippet: Primer sequences for RT-qPCR

Article Snippet: The membrane was then blocked in 5% skimmed milk at room temperature for 1 h, washed twice with PBS, and then incubated overnight at 4 °C with diluted rabbit anti-mouse primary antibodies against KCNMA1 (1:1000, MAB8589; AmyJet Scientific Inc., Wuhan, China), PKGII (1:1000, ab145063; Abcam, Inc., Cambridge, MA, USA), VASP (1:1000, ab58555; Abcam, USA), VEGF (1:1000, ab32152; Abcam, USA), Bax (1:1000, ab32503; Abcam, USA), Bcl-2 (1:1000, ab59348; Abcam, USA), Cyclin D1 (1:1000, ab134175, Abcam, USA), Cyclin D3 (1:1000, ab28283, Abcam, USA), Cdc 42 (1:1000, ab187643, Abcam, USA), caspase-3 (1:1000, ab208161, Abcam, USA), and PARP (1:1000, ab32064, Abcam, USA).

Techniques: Sequencing

Journal: Experimental & Molecular Medicine

Article Title: RETRACTED ARTICLE: Downregulation of the long noncoding RNA MBNL1-AS1 protects sevoflurane-pretreated mice against ischemia-reperfusion injury by targeting KCNMA1

doi: 10.1038/s12276-018-0133-y

Figure Lengend Snippet: a Images of skeletal muscle tissues acquired after immunohistochemistry assays. b Positive expression rate of KCNMA1. I/R ischemia-reperfusion, Sevo sevoflurane, KCNMA1 potassium calcium-activated channel subfamily M alpha 1; * p < 0.05 vs. the normal group; # p < 0.05 vs. the I/R group; scale bar = 25 µm; n = 10; measurement data are expressed as the mean ± standard deviation. Comparisons among multiple groups were performed by one-way ANOVA; the experiment was repeated 3 times

Article Snippet: The membrane was then blocked in 5% skimmed milk at room temperature for 1 h, washed twice with PBS, and then incubated overnight at 4 °C with diluted rabbit anti-mouse primary antibodies against KCNMA1 (1:1000, MAB8589; AmyJet Scientific Inc., Wuhan, China), PKGII (1:1000, ab145063; Abcam, Inc., Cambridge, MA, USA), VASP (1:1000, ab58555; Abcam, USA), VEGF (1:1000, ab32152; Abcam, USA), Bax (1:1000, ab32503; Abcam, USA), Bcl-2 (1:1000, ab59348; Abcam, USA), Cyclin D1 (1:1000, ab134175, Abcam, USA), Cyclin D3 (1:1000, ab28283, Abcam, USA), Cdc 42 (1:1000, ab187643, Abcam, USA), caspase-3 (1:1000, ab208161, Abcam, USA), and PARP (1:1000, ab32064, Abcam, USA).

Techniques: Immunohistochemistry, Expressing, Standard Deviation

Journal: Experimental & Molecular Medicine

Article Title: RETRACTED ARTICLE: Downregulation of the long noncoding RNA MBNL1-AS1 protects sevoflurane-pretreated mice against ischemia-reperfusion injury by targeting KCNMA1

doi: 10.1038/s12276-018-0133-y

Figure Lengend Snippet: a Relative mRNA expression of MBNL1-AS1, KCNMA1, PKGII, VASP, VEGF, Bax, and Bcl-2 in the skeletal muscle tissues of mice detected by RT-qPCR. b Protein bands observed after Western blot analysis. c Relative protein levels of KCNMA1, PKGII, VASP, p-PKGII, p-VASP, VEGF, Bax, and Bcl-2 in skeletal muscle tissues of mice evaluated by Western blot analysis. I/R ischemia-reperfusion, Sevo sevoflurane, MBNL1-AS1 muscleblind-like 1 antisense RNA 1, KCNMA1 potassium calcium-activated channel subfamily alpha 1, PKGII type II cyclic guanosine monophosphate-dependent protein kinase G, VASP vasodilator-stimulated phosphoprotein, VEGF vascular endothelial growth factor, Bcl-2 B-cell lymphoma/leukemia-2, Bax Bcl-2 associated X protein, GAPDH glyceraldehyde-3-phosphate dehydrogenase; * p < 0.05 vs. the normal group; # p < 0.05 vs. the I/R group; n = 10; measurement data are expressed as the mean ± standard deviation. Comparisons among multiple groups were performed by one-way ANOVA; the experiment was repeated 3 times

Article Snippet: The membrane was then blocked in 5% skimmed milk at room temperature for 1 h, washed twice with PBS, and then incubated overnight at 4 °C with diluted rabbit anti-mouse primary antibodies against KCNMA1 (1:1000, MAB8589; AmyJet Scientific Inc., Wuhan, China), PKGII (1:1000, ab145063; Abcam, Inc., Cambridge, MA, USA), VASP (1:1000, ab58555; Abcam, USA), VEGF (1:1000, ab32152; Abcam, USA), Bax (1:1000, ab32503; Abcam, USA), Bcl-2 (1:1000, ab59348; Abcam, USA), Cyclin D1 (1:1000, ab134175, Abcam, USA), Cyclin D3 (1:1000, ab28283, Abcam, USA), Cdc 42 (1:1000, ab187643, Abcam, USA), caspase-3 (1:1000, ab208161, Abcam, USA), and PARP (1:1000, ab32064, Abcam, USA).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Standard Deviation

Journal: Experimental & Molecular Medicine

Article Title: RETRACTED ARTICLE: Downregulation of the long noncoding RNA MBNL1-AS1 protects sevoflurane-pretreated mice against ischemia-reperfusion injury by targeting KCNMA1

doi: 10.1038/s12276-018-0133-y

Figure Lengend Snippet: a The predicted consequential pairing between MBNL1-AS1 and KCNMA1. b Relative luciferase activity in the NC, MBNL1-AS1 vector, and siRNA-MBNL1-AS1 groups determined by the dual-luciferase reporter gene assay. c RIP results in each group. MBNL1-AS1 muscleblind-like 1 antisense RNA 1, KCNMA1 potassium calcium-activated channel subfamily M alpha 1, si small interfering, NC negative control; * p < 0.05 vs. the NC group; measurement data are expressed as the mean ± standard deviation. Comparisons among multiple groups were performed by one-way ANOVA; the experiment was repeated 3 times

Article Snippet: The membrane was then blocked in 5% skimmed milk at room temperature for 1 h, washed twice with PBS, and then incubated overnight at 4 °C with diluted rabbit anti-mouse primary antibodies against KCNMA1 (1:1000, MAB8589; AmyJet Scientific Inc., Wuhan, China), PKGII (1:1000, ab145063; Abcam, Inc., Cambridge, MA, USA), VASP (1:1000, ab58555; Abcam, USA), VEGF (1:1000, ab32152; Abcam, USA), Bax (1:1000, ab32503; Abcam, USA), Bcl-2 (1:1000, ab59348; Abcam, USA), Cyclin D1 (1:1000, ab134175, Abcam, USA), Cyclin D3 (1:1000, ab28283, Abcam, USA), Cdc 42 (1:1000, ab187643, Abcam, USA), caspase-3 (1:1000, ab208161, Abcam, USA), and PARP (1:1000, ab32064, Abcam, USA).

Techniques: Luciferase, Activity Assay, Plasmid Preparation, Reporter Gene Assay, Negative Control, Standard Deviation

Journal: Experimental & Molecular Medicine

Article Title: RETRACTED ARTICLE: Downregulation of the long noncoding RNA MBNL1-AS1 protects sevoflurane-pretreated mice against ischemia-reperfusion injury by targeting KCNMA1

doi: 10.1038/s12276-018-0133-y

Figure Lengend Snippet: a RT-qPCR measured the relative mRNA expression of MBNL1-AS1, KCNMA1, PKGII, VASP, VEGF, Bax, and Bcl-2 in skeletal muscle cells after transfection. b Protein bands measured by Western blot analysis. c Western blot analysis measured the relative protein levels of KCNMA1, PKGII, VASP, p-PKGII, p-VASP, VEGF, Bax, and Bcl-2 in skeletal muscle cells after transfection. MBNL1-AS1 muscleblind-like 1 antisense RNA 1, KCNMA1 potassium calcium-activated channel subfamily M alpha 1, PKGII type II cyclic guanosine monophosphate-dependent protein kinase G, p-PKGII phosphorylated-PKGII, VASP vasodilator-stimulated phosphoprotein, p-VASP phosphorylated-VASP, VEGF vascular endothelial growth factor, Bcl-2 B-cell lymphoma/leukemia-2, Bax Bcl-2 associated X protein, si small interfering, GAPDH glyceraldehyde-3-phosphate dehydrogenase, NC negative control; * p < 0.05 vs. the control group; # p < 0.05 vs. the blank and NC groups; measurement data are expressed as the mean ± standard deviation. Comparisons among multiple groups were done. Comparisons among multiple groups were performed by one-way ANOVA; the experiment was repeated 3 times

Article Snippet: The membrane was then blocked in 5% skimmed milk at room temperature for 1 h, washed twice with PBS, and then incubated overnight at 4 °C with diluted rabbit anti-mouse primary antibodies against KCNMA1 (1:1000, MAB8589; AmyJet Scientific Inc., Wuhan, China), PKGII (1:1000, ab145063; Abcam, Inc., Cambridge, MA, USA), VASP (1:1000, ab58555; Abcam, USA), VEGF (1:1000, ab32152; Abcam, USA), Bax (1:1000, ab32503; Abcam, USA), Bcl-2 (1:1000, ab59348; Abcam, USA), Cyclin D1 (1:1000, ab134175, Abcam, USA), Cyclin D3 (1:1000, ab28283, Abcam, USA), Cdc 42 (1:1000, ab187643, Abcam, USA), caspase-3 (1:1000, ab208161, Abcam, USA), and PARP (1:1000, ab32064, Abcam, USA).

Techniques: Quantitative RT-PCR, Expressing, Transfection, Western Blot, Negative Control, Standard Deviation

Journal: Experimental & Molecular Medicine

Article Title: RETRACTED ARTICLE: Downregulation of the long noncoding RNA MBNL1-AS1 protects sevoflurane-pretreated mice against ischemia-reperfusion injury by targeting KCNMA1

doi: 10.1038/s12276-018-0133-y

Figure Lengend Snippet: a Cell proliferation in each group as measured by MTT. b Cell proliferation in each group as measured by EdU. c Cell proliferation in each group as measured by EdU (×50). OD optical density, MBNL1-AS1 muscleblind-like 1 antisense RNA 1, KCNMA1 potassium calcium-activated channel subfamily M alpha 1, si small interfering, NC negative control; * p < 0.05 vs. the control group; # p < 0.05 vs. the blank and NC groups; scale bar = 200 µm; the experiment was repeated 3 times

Article Snippet: The membrane was then blocked in 5% skimmed milk at room temperature for 1 h, washed twice with PBS, and then incubated overnight at 4 °C with diluted rabbit anti-mouse primary antibodies against KCNMA1 (1:1000, MAB8589; AmyJet Scientific Inc., Wuhan, China), PKGII (1:1000, ab145063; Abcam, Inc., Cambridge, MA, USA), VASP (1:1000, ab58555; Abcam, USA), VEGF (1:1000, ab32152; Abcam, USA), Bax (1:1000, ab32503; Abcam, USA), Bcl-2 (1:1000, ab59348; Abcam, USA), Cyclin D1 (1:1000, ab134175, Abcam, USA), Cyclin D3 (1:1000, ab28283, Abcam, USA), Cdc 42 (1:1000, ab187643, Abcam, USA), caspase-3 (1:1000, ab208161, Abcam, USA), and PARP (1:1000, ab32064, Abcam, USA).

Techniques: Negative Control

Journal: Experimental & Molecular Medicine

Article Title: RETRACTED ARTICLE: Downregulation of the long noncoding RNA MBNL1-AS1 protects sevoflurane-pretreated mice against ischemia-reperfusion injury by targeting KCNMA1

doi: 10.1038/s12276-018-0133-y

Figure Lengend Snippet: a Cell cycle of skeletal muscle cells in seven groups as detected by flow cytometry. b Apoptosis of skeletal muscle cells in seven groups as detected by flow cytometry. MBNL1-AS1 muscleblind-like 1 antisense RNA 1, KCNMA1 potassium calcium-activated channel subfamily M alpha 1, si small interfering, NC negative control; * p < 0.05 vs. the control group; # p < 0.05 vs. the blank and NC groups; measurement data are expressed as the mean ± standard deviation. Comparisons among multiple groups were performed by one-way ANOVA; the experiment was repeated 3 times

Article Snippet: The membrane was then blocked in 5% skimmed milk at room temperature for 1 h, washed twice with PBS, and then incubated overnight at 4 °C with diluted rabbit anti-mouse primary antibodies against KCNMA1 (1:1000, MAB8589; AmyJet Scientific Inc., Wuhan, China), PKGII (1:1000, ab145063; Abcam, Inc., Cambridge, MA, USA), VASP (1:1000, ab58555; Abcam, USA), VEGF (1:1000, ab32152; Abcam, USA), Bax (1:1000, ab32503; Abcam, USA), Bcl-2 (1:1000, ab59348; Abcam, USA), Cyclin D1 (1:1000, ab134175, Abcam, USA), Cyclin D3 (1:1000, ab28283, Abcam, USA), Cdc 42 (1:1000, ab187643, Abcam, USA), caspase-3 (1:1000, ab208161, Abcam, USA), and PARP (1:1000, ab32064, Abcam, USA).

Techniques: Flow Cytometry, Negative Control, Standard Deviation

Journal: Experimental & Molecular Medicine

Article Title: RETRACTED ARTICLE: Downregulation of the long noncoding RNA MBNL1-AS1 protects sevoflurane-pretreated mice against ischemia-reperfusion injury by targeting KCNMA1

doi: 10.1038/s12276-018-0133-y

Figure Lengend Snippet: Apoptosis rate and cell cycle distribution of skeletal muscle cells among seven groups

Article Snippet: The membrane was then blocked in 5% skimmed milk at room temperature for 1 h, washed twice with PBS, and then incubated overnight at 4 °C with diluted rabbit anti-mouse primary antibodies against KCNMA1 (1:1000, MAB8589; AmyJet Scientific Inc., Wuhan, China), PKGII (1:1000, ab145063; Abcam, Inc., Cambridge, MA, USA), VASP (1:1000, ab58555; Abcam, USA), VEGF (1:1000, ab32152; Abcam, USA), Bax (1:1000, ab32503; Abcam, USA), Bcl-2 (1:1000, ab59348; Abcam, USA), Cyclin D1 (1:1000, ab134175, Abcam, USA), Cyclin D3 (1:1000, ab28283, Abcam, USA), Cdc 42 (1:1000, ab187643, Abcam, USA), caspase-3 (1:1000, ab208161, Abcam, USA), and PARP (1:1000, ab32064, Abcam, USA).

Techniques: Plasmid Preparation

Journal: International Orthopaedics

Article Title: Abnormal expression of chondroitin sulphate N-acetylgalactosaminyltransferase 1 and Hapln-1 in cartilage with Kashin–Beck disease and primary osteoarthritis

doi: 10.1007/s00264-013-1937-y

Figure Lengend Snippet: Chondrocyte gene network of CSGalNAcT-1 was classified as glycan biosynthesis and metabolism and functional pathway

Article Snippet: For the primary antibody, polyclonal rabbit anti-human primary antibodies against CSGalNAcT-1 (1:50; ABGENT, San Diego, CA 92121, USA) and Hapln-1 (1:50; Abcam, UK) were used at 4 ° C overnight.

Techniques: Functional Assay

Journal: International Orthopaedics

Article Title: Abnormal expression of chondroitin sulphate N-acetylgalactosaminyltransferase 1 and Hapln-1 in cartilage with Kashin–Beck disease and primary osteoarthritis

doi: 10.1007/s00264-013-1937-y

Figure Lengend Snippet: CSGalNAcT-1 and Hapln-1 mRNA expression in osteoarthritis (OA) cartilage, Kashin-Beck disease (KBD) cartilage and normal cartilage. CSGalNAcT-1 and Hapln-1 mRNA levels reach statistical significance. * Denotes significant difference at P < 0.05

Article Snippet: For the primary antibody, polyclonal rabbit anti-human primary antibodies against CSGalNAcT-1 (1:50; ABGENT, San Diego, CA 92121, USA) and Hapln-1 (1:50; Abcam, UK) were used at 4 ° C overnight.

Techniques: Expressing

Journal: International Orthopaedics

Article Title: Abnormal expression of chondroitin sulphate N-acetylgalactosaminyltransferase 1 and Hapln-1 in cartilage with Kashin–Beck disease and primary osteoarthritis

doi: 10.1007/s00264-013-1937-y

Figure Lengend Snippet: Comparison of CSGalNAcT-1 expression in the cartilage from osteoarthritis (OA), Kashin-Beck disease (KBD) and normal groups. a , b , c Denote the upper of normal, OA and KBD cartilage, respectively. d , e , f Denote the middle of normal, OA and KBD cartilage, respectively. g , h , i Denote the deep of normal, OA and KBD cartilage, respectively

Article Snippet: For the primary antibody, polyclonal rabbit anti-human primary antibodies against CSGalNAcT-1 (1:50; ABGENT, San Diego, CA 92121, USA) and Hapln-1 (1:50; Abcam, UK) were used at 4 ° C overnight.

Techniques: Expressing

Journal: International Orthopaedics

Article Title: Abnormal expression of chondroitin sulphate N-acetylgalactosaminyltransferase 1 and Hapln-1 in cartilage with Kashin–Beck disease and primary osteoarthritis

doi: 10.1007/s00264-013-1937-y

Figure Lengend Snippet: CSGalNAcT-1 and Hapln-1 protein level expression reduced in osteoarthritis (OA) and Kashin-Beck disease (KBD) cartilage compared with normal controls. Wnt 3a, β-catenin and Runx-2 level expression increased in OA and KBD cartilage compared with normal controls. A KBD free-Se group. B 0.25 μg/ml Se + KBD group. C 0.10 μg/ml Se + KBD group. D 0.05 μg/ml Se + KBD group

Article Snippet: For the primary antibody, polyclonal rabbit anti-human primary antibodies against CSGalNAcT-1 (1:50; ABGENT, San Diego, CA 92121, USA) and Hapln-1 (1:50; Abcam, UK) were used at 4 ° C overnight.

Techniques: Expressing